Next Science hit by Covid-19 shutdowns

Wound care technology developer Next Science was hit by shutdowns of elective surgeries and wound care clinics in the United States during the first six months of 2020, curbing revenue.

Sales for the six months were $1.9 million, a small reduction on the previous corresponding period.

Sales of Bactisure wound wash, BlastX anti-microbial wound gel and SurgX hospital product have begun to recover as the economy reopens, however the company warns of the potential for further market disruptions.

The company’s acne creams, gels and cleanser continued to grow during the pandemic through online sales.

The products are based on the company’s patented Xbio technology which attacks the biofilm that surrounds and protects bacteria.

Over the next six months the company plans to launch Bactisure in Europe and Australia, and to begins sales of BlastX in Canada.

The company’s newest product XPerience Surgical Rinse will also be launched in the US, offering surgeons the first anti-microbial solution that can be left in a surgical cavity.

XPerience replaces some of the saline rinses used in surgical procedures.

Picture: Next Science

Subscribe to our free @AuManufacturing newsletter here.